FDA Approves Libtayo® as Monotherapy for Advanced NSCLC
FDA Approves Libtayo® as Monotherapy for Advanced NSCLC Search jobs Subject: FDA Approves Libtayo Regeneron and Sanofi received U.S. FDA approval for Libtayo® (cemiplimab-rwlc, an PD-1 inhibitor) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score ≥50%), %), as determined by an FDA-approved test. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation, and the tumors must not have EGFR, ALK or ROS1 ...
Source: pharmiweb.com